XOMA Earnings Estimate

XOMA Earnings per Share Projection vs Actual

About XOMA Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of XOMA earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current XOMA estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as XOMA fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. Xoma Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.

Pair Trading with XOMA

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if XOMA position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in XOMA will appreciate offsetting losses from the drop in the long position's value.

Moving against XOMA Preferred Stock

  0.88UPB Upstream Bio,PairCorr
  0.84JUNS Jupiter Neurosciences,PairCorr
  0.73ZBIO Zenas BioPharma, CommonPairCorr
  0.67GRCE Grace Therapeutics, Symbol ChangePairCorr
  0.63HURA TuHURA Biosciences Symbol ChangePairCorr
The ability to find closely correlated positions to XOMA could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace XOMA when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back XOMA - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling XOMA Corporation to buy it.
The correlation of XOMA is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as XOMA moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if XOMA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for XOMA can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in XOMA Preferred Stock

XOMA financial ratios help investors to determine whether XOMA Preferred Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XOMA with respect to the benefits of owning XOMA security.